Predicting IVF Success: How 1D-CNN AI Identifies Alloimmune Risks Before Embryo Transfer

For many aspiring parents, In Vitro Fertilization (IVF) feels like the ultimate solution. However, the emotional and financial toll of a failed cycle—often costing upwards of $20,000—remains a harsh reality. While chromosomal abnormalities in embryos are frequently blamed, a significant percentage of unexplained IVF failures and recurrent pregnancy loss (RPL) root back to maternal biological readiness, specifically immune-driven rejection.

The Hidden Threat: Alloimmune Rejection Patterns

During a healthy pregnancy, the maternal immune system must undergo a complex shift to tolerate the embryo, which carries foreign paternal genetic material. When this tolerance mechanism fails, the body misidentifies the embryo as a threat, leading to alloimmune rejection.

Traditional diagnostics struggle to detect these subtle immune shifts early. They often require invasive tissue biopsies or rely on slow, low-sensitivity assays that only capture damage after clinical symptoms or pregnancy loss occur.

Shifting from Reactive to Predictive MedTech

Protthera is changing this paradigm by introducing an asset-light, non-invasive diagnostic protocol. Instead of invasive procedures, we isolate key signals from a simple maternal blood draw, specifically focusing on Circulating Immune Complexes (CICs) and proteomic damage patterns.

The core of our platform lies in proprietary 1D-CNN (One-Dimensional Convolutional Neural Network) algorithms. Why deep learning?

• Unmatched Speed: Our algorithms process complex proteomic data 20x faster than traditional ELISA laboratory methods.
• High Sensitivity: The AI maps molecular patterns associated with immune damage (MPAAD) long before they manifest as a clinical failure.
• Actionable Scores: Doctors receive a definitive “Biological Readiness Score,” allowing them to delay embryo transfer or adjust immunomodulatory therapies until the maternal body is truly ready.

Real-World Validation: The Warsaw Clinical Pilot

As we move into Q3 2026, Protthera is launching a high-accuracy validation study in Warsaw, Poland. Partnering with leading local gynecological and reproductive clinics, the 50-patient clinical pilot will focus exclusively on validating our 1D-CNN pattern recognition for women planning pregnancy or undergoing IVF.

By reducing diagnostic costs by 40% ($600 entry point vs €1,000+ market alternatives), we aim to make precision reproductive diagnostics a standard pre-pregnancy check, transforming how the global medical community approaches maternal wellness and embryo implantation.